Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS

American Heart Journal

Volumn 152, Issue 4, 2006, Pages 684.e1-684.e9

  Sinnaeve, Peter R ^a   Huang, Yao ^b   Bogaerts, Kris ^a   Vahanian, Alec ^c   Adgey, Jennifer ^d   Armstrong, Paul W ^e   Wallentin, Lars ^f   Van de Werf, Frans J ^a   Granger, Christopher B ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c BICHAT HOSPITAL   (France)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TENECTEPLASE;

ACUTE HEART INFARCTION; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; FEMALE; GERIATRIC PATIENT; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33748708210     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.07.005     Document Type: Article

References (24)

1. Lee K.L., Woodlief L.H., Topol E.J., et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 91 (1995) 1659
2. Stevenson R., Ranjadayalan K., Wilkinson P., et al. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ 307 (1993) 349
3. Goldberg R.J., McCormick D., Gurwitz J.H., et al. Age-related trends in short-and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975-1995). Am J Cardiol 82 (1998) 1311
4. Maggioni A.P., Maseri A., Fresco C., et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The investigators of the gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico (GISSI-2). N Engl J Med 329 (1993) 1442
5. Paul S.D., O'Gara P.T., Mahjoub Z.A., et al. Geriatric patients with acute myocardial infarction: cardiac risk factor profiles, presentation, thrombolysis, coronary interventions, and prognosis. Am Heart J 131 (1996) 710
6. Thiemann D.R., Coresh J., Schulman S.P., et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 101 (2000) 2239
7. Weaver W.D., Litwin P.E., Martin J.S., et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. The MITI Project Group. J Am Coll Cardiol 18 (1991) 657
8. White H.D., Barbash G.I., Califf R.M., et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 94 (1996) 1826
9. Antman E.M., Gibson C.M., de Lemos J.A., et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The thrombolysis in myocardial infarction (TIMI) 14 Investigators. Eur Heart J 21 (2000) 1944
10. Giugliano R.P., Roe M., Harrington R., et al. Combination reperfusion therapy with eptifibatide and reduced dose tenecteplase for ST-elevation myocardial infarction: results of the Integrilin and tenecteplase in acute myocardial infarction trial (INTEGRITI) phase II angiographic trial. J Am Coll Cardiol 14 (2003) 1251-1260
11. Topol E.J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357 (2001) 1905
12. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605
13. Wallentin L., Goldstein P., Armstrong P.W., et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 108 (2003) 135
14. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895
15. Casterella P.J., Kereiakes D.J., Steinhubl S.R., et al. The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable. Catheter Cardiovasc Interv 54 (2001) 497
16. Becker R.C., Spencer F.A., Gibson M., et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143 (2002) 753
17. Sabatine M.S., Morrow D.A., Montalescot G., et al. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation 112 (2005) 3846-3854
18. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
19. Montalescot G., Collet J.P., Tanguy M.L., et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110 (2004) 392-398
20. Baird S.H., Menown I.B., McBride S.J., et al. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 23 (2002) 627
21. Tran C.T., Laupacis A., Mamdani M.M., et al. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Am Heart J 148 (2004) 834-841
22. Spencer F.A., Goldberg R.J., Frederick P.D., et al. Age and the utilization of cardiac catheterization following uncomplicated first acute myocardial infarction treated with thrombolytic therapy (The Second National Registry of Myocardial Infarction [NRMI-2]). Am J Cardiol 88 (2001) 107
23. Alexander K.P., Galanos A.N., Jollis J.G., et al. Post-myocardial infarction risk stratification in elderly patients. Am Heart J 142 (2001) 37
24. Aguirre F.V., McMahon R.P., Mueller H., et al. Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators. Circulation 90 (1994) 78